DGAP-News: Press Release: 4SC AG further strengthens Supervisory Board with experienced managers from the pharmaceutical industry

DGAP-News: 4SC AG / Key word(s): Change of Personnel/AGM/EGM
Press Release: 4SC AG further strengthens Supervisory Board with
experienced managers from the pharmaceutical industry

06.08.2012 / 13:27

---------------------------------------------------------------------

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR ANY JURISDICTION WHERE
TO DO SO WOULD CONSTITUTE A VIOLATION OF APPLICABLE LAWS OR REGULATIONS

Press Release 

4SC AG further strengthens Supervisory Board with experienced managers from
the pharmaceutical industry

Planegg-Martinsried, Germany, 6 August, 2012 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for autoimmune and cancer diseases, today announced the
appointment of Dr Irina Antonijevic and Mr Klaus Kühn to the company's
Supervisory Board.

In a by-election at today's Annual General Meeting of 4SC AG, Dr
Antonijevic and Mr Kühn were elected to the Supervisory Board for the
remaining term of Dr Jörg Neermann and Mr Günter Frankenne, who have
stepped down from the Supervisory Board. The terms of office will run until
the end of the Annual General Meeting that resolves on formally approving
the actions of the Supervisory Board for financial year 2012.

Dr Antonijevic, Director Clinical Research at US pharmaceutical company
Sanofi, has many years of international experience in clinical drug
development and extensive expertise gained in executive positions both in
the pharmaceutical industry and in medical research in a university
environment.

Klaus Kühn, former Chief Financial Officer of Bayer AG (2002 to 2010), has
more than 30 years of experience in executive positions primarily in the
chemical and pharmaceutical industry with a focus on finance and
accounting.

The shareholders of 4SC AG also approved all of the resolutions proposed to
the Annual General Meeting by the Management Board and the Supervisory
Board with the required majority, including the following items:

  - Resolution on the approval of the remuneration system for members of
    the Management Board;

  - Approval of a control and profit transfer agreement between 4SC AG and
    4SC Discovery GmbH;

  - Resolution on the creation of new Authorised Capital, adjusted to the
    share capital that was raised following the capital increase in June
    2012;

  - Resolution on a new authorisation of the Management Board to issue
    convertible bonds, bonds with warrants, profit participation rights
    and/or income debentures and create corresponding Conditional Capital.

A total of 78.3% of the voting capital was represented at the 2012 Annual
General Meeting of 4SC AG.

Ends

About 4SC 

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various autoimmune and cancer indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's balanced pipeline comprises promising products that are
in various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
leading pharmaceutical companies. Founded in 1997, 4SC had 90 employees at
31 March 2012. 4SC AG has been listed on the Prime Standard of the
Frankfurt Stock Exchange since December 2005.

Legal Note

This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.

For more information please visit www.4sc.com or contact:

4SC AG 
Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66

MC Services 
Mareike Mohr
Mareike.mohr(at)mc-services.eu , Tel.: +49 (0) 89 21 02 28 40


End of Corporate News

---------------------------------------------------------------------

06.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                
Company:     4SC AG                                                 
             Am Klopferspitz 19a                                    
             82152 Martinsried                                      
             Germany                                                
Phone:       +49 (0)89 7007 63-0                                    
Fax:         +49 (0)89 7007 63-29                                   
E-mail:      public@4sc.com                                         
Internet:    www.4sc.de                                             
ISIN:        DE0005753818                                           
WKN:         575381                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
180372 06.08.2012